Ramaswamy's Roivant Inks $650M R&D Deal With This Tiny Diabetes Biotech Post author:Sam Post published:February 11, 2018 Post category:BioPharma With the deal in hand, Roivant has stepped into the world of metabolic diseases. Source: BioSpace You Might Also Like Mallinckrodt Advocates For Comprehensive, Multi-Prong Action Plan To Fight Opioid Abuse And Misuse In The United States September 24, 2017 FDA Calls Bay Area Zogenix's Dravet Syndrome Drug a Breakthrough February 5, 2018 Why the Best is Yet to Come for This Tiny Massachusetts Biotech November 27, 2017
Mallinckrodt Advocates For Comprehensive, Multi-Prong Action Plan To Fight Opioid Abuse And Misuse In The United States September 24, 2017
